PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
Abstract The therapeutic potential of immune checkpoint inhibitors is currently being investigated in epithelial ovarian cancer (EOC), but immunological effects of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis in EOC still remain poorly understood. The aim...
Guardado en:
Autores principales: | Christine Bekos, Dietmar Pils, Sabine Dekan, Gerda Hofstetter, Peter Horak, Alexander Reinthaller, Stephan Polterauer, Richard Schwameis, Stefanie Aust |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f6b4df31ae53472281d4202e85652f46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021) -
Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Anna Pawłowska, et al.
Publicado: (2021) -
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021)